FILTER
FILTERED INTERVIEW RESULTS
Michael Quirmbach
CEO & PRESIDENT, CORDENPHARMA
CordenPharma is enjoying great demand for its increasing array of services.
Alan Petro
CEO, NEW VISION PHARMACEUTICALS
New Vision Pharmaceuticals explains how it is developing Blow-Fill-Seal technology and other services.
Thomas E. Bowens
FOUNDER AND PRESIDENT, IG GLOBAL GROUP & PRESIDENT AND CEO, TINTIC CONSOLIDATED METALS
Tintic Consolidated Metals explains to GBR how it is exploring the its’ vast gold/copper project in the Tintic district in Utah.
Manni Kantipudi & Ramesh Subramanian
CEO & CCO, ARAGEN LIFE SCIENCES
Aragen Life Sciences continues its rapid expansion and celebrates its best year ever.
Jose Antonio Moreno Toscano
CEO, LFB USA
LFB speaks to GBR as it begins the commercialization of Sevenfact and ATryn.
Dr. Siva Samy
CEO & CHIEF PRODUCT STRATEGIST, VALGENESIS
ValGenesis explains how it streamlines the validation process to allow real-time access to validation documents and data enabling various stakeholders to achieve compliance efficiently.
Michael Kauffman
CEO, KARYOPHARM THERAPEUTICS
GBR speaks to Karyopharm Therapeutics about the commercialization of XPOVIO.
Eric Ostertag M.D., Ph.D.
CEO, POSEIDA THERAPEUTICS
Poseida Therapeutics explains how progress in gene therapy offers the possibility to provide single treatment cures for cancer and other genetic diseases.
Amit Munshi
PRESIDENT & CEO, ARENA PHARMACEUTICALS
Arena Pharmaceuticals speaks to GBR about building its pipeline and infrastructure.
Dr. Andrea Pfeifer
CO-FOUNDER & CEO, AC IMMUNE
AC Immune describes its research into neurodegenerative diseases.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
